1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The successful completion of this Phase 1/1b study is crucial for advancing TLC-6740 as a potential novel therapeutic agent for obesity and Type 2 Diabetes, conditions that continue to pose significant public health c…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This research provides crucial, granular insights into the stability and efficacy of Salcaprozate Sodium as an oral absorption enhancer under diverse physiological conditions. Understanding how various GI factors affe…
This comprehensive toxicological profile provides a crucial foundation for understanding the safety landscape of existing anti-diabetic drugs and informing the development of safer next-generation therapies. The ident…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
The findings suggest that GLP-1 Receptor Agonists could represent a novel, multi-faceted therapeutic strategy for stroke, offering both acute neuroprotection and long-term secondary prevention. Their ability to reduce…
This research highlights a novel, non-glycemic benefit of Tirzepatide, suggesting its potential beyond glucose and weight management. The ability of Tirzepatide to significantly enhance angiogenesis and improve blood …
This study highlights a critical safety signal, suggesting that GLP-1 receptor agonists may be associated with an increased risk of depressed mood and suicidal ideation in real-world settings. This finding underscores…
This study provides crucial evidence for clinicians and patients, highlighting the distinct advantages of metabolic and bariatric surgery in achieving more profound and sustained improvements in cardiometabolic risk p…
This case highlights a potential adverse dermatological reaction to tirzepatide, suggesting that GLP-1/GIP receptor agonists might, in rare instances, trigger or exacerbate autoimmune conditions like psoriasis. This o…
This comprehensive review underscores Semaglutide's robust potential as an effective pharmacological intervention for chronic weight management in non-diabetic adults. The consistent and substantial weight loss, coupl…
These findings provide compelling evidence that tirzepatide can fundamentally alter the disease classification for a significant number of individuals with obesity and overweight, moving them into lower-risk BMI categ…
Tirzepatide not only facilitates significant weight loss but also enables a substantial proportion of individuals with obesity to achieve healthier BMI categories, which is directly associated with profound improvemen…
This review highlights Tirzepatide's potential as a valuable adjunct therapy for managing the complex challenges of Type 1 Diabetes complicated by overweight or obesity. The dual benefits of improved glycemic control …
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
This study is critically important because semaglutide (NN9535) is a widely used and highly effective treatment for Type 2 Diabetes. Understanding its pharmacokinetic profile in patients with renal impairment is vital…
While specific results for the OASIS 3 trial are currently pending publication, this Phase 3 study was designed to demonstrate significant body weight reduction. Based on the established efficacy of semaglutide as a G…
This Phase 2 trial is highly significant as it explores a potential novel adjunctive therapy for Type 2 Diabetes patients who are not adequately controlled by current GLP-1-based treatments. If icovamenib proves effec…
Demonstrating the clinical comparability of drug products from different manufacturing processes is crucial for ensuring consistent drug quality, safety, and patient outcomes globally. This study's findings, once rele…
Preserving lean muscle mass during rapid weight loss is critical for maintaining metabolic rate, improving insulin sensitivity, and preventing weight regain, especially in individuals with Type 2 Diabetes Mellitus. Th…
Understanding the precise impact of dosing variations on oral semaglutide pharmacokinetics is crucial for optimizing patient outcomes and adherence. This study provides robust data that reinforces the importance of cu…
This study is highly significant because it could establish Tirzepatide as a novel therapeutic agent for directly improving cardiovascular health in overweight and obese individuals with existing Coronary Artery Disea…
This study provides crucial dose-response data for NNC0519-0130, suggesting it could be a highly effective once-weekly treatment for Type 2 Diabetes. The observed significant reductions in HbA1c and body weight, coupl…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
Obesity is a major comorbidity in breast cancer patients, negatively impacting treatment efficacy and increasing recurrence risk. This study is significant because it directly addresses the potential of a powerful wei…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
This study provides compelling evidence that tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is significantly more effective than semaglutid…
This comprehensive review underscores the significant potential of GLP-1 receptor agonists as a novel therapeutic strategy for stroke prevention, particularly in patients with type 2 diabetes and obesity. Their abilit…
This case report highlights the potential efficacy and safety of GLP-1 receptor agonists (GLP1RAs), specifically semaglutide, in managing the challenging glycemic control associated with mitochondrial diabetes in pedi…
This study's findings are highly significant as they highlight the potential for semaglutide, a widely utilized medication, to improve fertility prospects within a challenging patient population. Obesity-related infer…
This research provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer a novel therapeutic approach to improve outcomes for obese patients after TAVR. By significantly reducing subcl…
This study provides compelling evidence that combining GLP-1 receptor agonists with progestin therapy could be a highly effective and safe fertility-sparing treatment for EIN and early-stage endometrial cancer. The si…
This review highlights a paradigm shift in how dysglycemia might be managed in acute care settings. If GLP-1 RAs prove safe and effective in this population, they could offer a novel therapeutic strategy to improve ou…
Improved device design, particularly through automation, can significantly enhance patient safety and adherence for chronic conditions requiring frequent self-injection, such as type 2 diabetes and obesity. Reducing c…
The systematic review identified a consistent, albeit variable, reporting of hair loss among patients receiving GLP-1 receptor agonists. Across the analyzed studies, the incidence of alopecia ranged from approximately…
This systematic review provides compelling evidence that incretin-based therapies offer superior body composition benefits, promoting greater fat loss while better preserving crucial lean muscle mass, which is vital f…
This study provides crucial evidence that semaglutide is highly effective and well-tolerated in young adults with Type 2 Diabetes, a population facing unique challenges in disease management. The significant improveme…
This study provides robust real-world evidence suggesting a neuroprotective role for GLP-1 RAs, potentially offering a novel strategy for Parkinson's disease prevention or delaying its onset. These findings could pave…
This study provides compelling preclinical evidence that Semaglutide, a widely used GLP-1 receptor agonist, possesses significant neuroprotective properties against ischemic brain injury by targeting ferroptosis. The …
This Phase 3 study, consistent with other trials, further validates semaglutide 2.4 mg as a highly effective pharmacological intervention for the treatment of obesity and overweight. The robust and sustained weight lo…
This follow-up study is critical for understanding the sustained impact of semaglutide on cardiovascular health and weight management after treatment cessation. The insights gained could inform long-term treatment str…
This pilot study is crucial because it addresses a significant unmet need for effective smoking cessation strategies in Type 2 diabetes patients, a group at high risk for cardiovascular complications. If semaglutide p…
The successful completion of this Phase 3 trial suggests semaglutide 2.4 mg could represent a significant advancement in the management of obesity and prediabetes. If the full results confirm substantial weight loss a…
If BGM0504 demonstrates comparable or superior efficacy to semaglutide with a favorable safety profile, it could represent a significant new therapeutic option for managing Type 2 Diabetes. This could provide a valuab…